{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:05:51Z","timestamp":1777046751635,"version":"3.51.4"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1013192","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000}}],"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA261277-02"],"award-info":[{"award-number":["U01CA261277-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generates an antibody response that shows large inter-individual variability. This variability complicates the use of antibody levels as a correlate of protection and the evaluation of population- and individual-level infection risk without access to broad serological testing. Here, we applied a mathematical model of antibody kinetics to capture individual anti-SARS-CoV-2 IgG antibody trajectories and to identify factors driving the humoral immune response. Subsequently, we evaluated model predictions and inferred the corresponding duration of protection for new individuals based on a single antibody measurement, assuming sparse access to serological testing. We observe a reduced antibody response in older and in male individuals, and in individuals with autoimmune diseases, diabetes and immunosuppression, using data from a longitudinal cohort study conducted in healthcare workers at Sheba Medical Center, Israel, following primary vaccination with the BNT162b2 COVID-19 vaccine. Our results further suggest that model predictions of an individual\u2019s antibody response to vaccination can be used to predict the duration of protection when serological data is limited, highlighting the potential of our approach to estimate infection risk over time on both the population and individual level to support public health decision-making in future pandemics.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1013192","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T13:58:36Z","timestamp":1750255116000},"page":"e1013192","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predicting antibody kinetics and duration of protection against SARS-CoV-2 following vaccination from sparse serological data"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1364-908X","authenticated-orcid":true,"given":"Julia","family":"Deichmann","sequence":"first","affiliation":[]},{"given":"Noam","family":"Barda","sequence":"additional","affiliation":[]},{"given":"Michal","family":"Canetti","sequence":"additional","affiliation":[]},{"given":"Yovel","family":"Peretz","sequence":"additional","affiliation":[]},{"given":"Yael","family":"Weiss-Ottolenghi","sequence":"additional","affiliation":[]},{"given":"Yaniv","family":"Lustig","sequence":"additional","affiliation":[]},{"given":"Gili","family":"Regev-Yochay","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-9213","authenticated-orcid":true,"given":"Marc","family":"Lipsitch","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"27","key":"pcbi.1013192.ref001","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"pcbi.1013192.ref002","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 Months","volume":"385","author":"SJ Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"pcbi.1013192.ref003","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","article-title":"Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom","volume":"27","author":"E Pritchard","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"pcbi.1013192.ref004","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJMc2107717","article-title":"Effect of vaccination on household transmission of SARS-CoV-2 in England","volume":"385","author":"RJ Harris","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"pcbi.1013192.ref005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Y Goldberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"pcbi.1013192.ref006","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"M Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"pcbi.1013192.ref007","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"pcbi.1013192.ref008","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/infdis\/jiac403","article-title":"The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults","volume":"227","author":"M Asamoah-Boaheng","year":"2023","journal-title":"J Infect Dis"},{"issue":"9","key":"pcbi.1013192.ref009","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/infdis\/jiab375","article-title":"Kinetics of the severe acute respiratory syndrome coronavirus 2 antibody response and serological estimation of time since infection","volume":"224","author":"S Pelleau","year":"2021","journal-title":"J Infect Dis"},{"issue":"3","key":"pcbi.1013192.ref010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"MK Slifka","year":"1998","journal-title":"Immunity"},{"issue":"1","key":"pcbi.1013192.ref011","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1038\/s41467-022-33550-z","article-title":"Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study","volume":"13","author":"M Shrotri","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"pcbi.1013192.ref012","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41467-024-45468-9","article-title":"Demographic and clinical factors associated with SARS-CoV-2 spike 1 antibody response among vaccinated US adults: the C4R study","volume":"15","author":"JS Kim","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"pcbi.1013192.ref013","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/infdis\/jiu219","article-title":"Dynamics of the antibody response to Plasmodium falciparum infection in African children","volume":"210","author":"MT White","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"pcbi.1013192.ref014","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1038\/s41467-023-38744-7","article-title":"Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1\/BA.2 infection","volume":"14","author":"J Perez-Saez","year":"2023","journal-title":"Nat Commun"},{"issue":"24","key":"pcbi.1013192.ref015","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"EG Levin","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"pcbi.1013192.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00012-5","article-title":"Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study","volume":"4","author":"G Regev-Yochay","year":"2023","journal-title":"Lancet Microbe"},{"issue":"6","key":"pcbi.1013192.ref017","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41590-022-01212-3","article-title":"Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose","volume":"23","author":"Y Lustig","year":"2022","journal-title":"Nat Immunol"},{"issue":"9","key":"pcbi.1013192.ref018","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","article-title":"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers","volume":"9","author":"Y Lustig","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7872","key":"pcbi.1013192.ref019","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"DA Collier","year":"2021","journal-title":"Nature"},{"issue":"48","key":"pcbi.1013192.ref020","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1016\/j.vaccine.2021.10.038","article-title":"COVID-19 vaccine\u2014long term immune decline and breakthrough infections","volume":"39","author":"J Khoury","year":"2021","journal-title":"Vaccine"},{"issue":"47","key":"pcbi.1013192.ref021","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1016\/j.vaccine.2021.10.016","article-title":"Single BNT162b2 vaccine dose produces seroconversion in under 60\u2009s cohort","volume":"39","author":"Y Shachor-Meyouhas","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"pcbi.1013192.ref022","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s12879-022-07262-0","article-title":"Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies","volume":"22","author":"D Herrera-Esposito","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"5","key":"pcbi.1013192.ref023","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/infdis\/jiab314","article-title":"COVID-19 mRNA vaccination generates greater immunoglobulin G levels in women compared to men","volume":"224","author":"AR Demonbreun","year":"2021","journal-title":"J Infect Dis"},{"issue":"6","key":"pcbi.1013192.ref024","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2213-8587(21)00089-9","article-title":"Associations between body-mass index and COVID-19 severity in 6\u00b79 million people in England: a prospective, community-based, cohort study","volume":"9","author":"M Gao","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"pcbi.1013192.ref025","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41591-023-02343-2","article-title":"Accelerated waning of the humoral response to COVID-19 vaccines in obesity","volume":"29","author":"AA van der Klaauw","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"pcbi.1013192.ref026","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"M Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"pcbi.1013192.ref027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011282","article-title":"Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2","volume":"19","author":"Q Clairon","year":"2023","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"pcbi.1013192.ref028","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12916-024-03304-3","article-title":"Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination","volume":"22","author":"P\u00e9rez Mart\u00edn","year":"2024","journal-title":"BMC Med"},{"issue":"1","key":"pcbi.1013192.ref029","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-023-42717-1","article-title":"Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time","volume":"14","author":"G Kenny","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pcbi.1013192.ref030","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1038\/s41598-024-57931-0","article-title":"Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-na\u00efve adults receiving the first four mRNA COVID-19 vaccine doses","volume":"14","author":"T Matsuura","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"pcbi.1013192.ref031","article-title":"Understanding \u201chybrid immunity\u201d: comparison and predictors of humoral immune responses to severe acute respiratory syndrome coronavirus 2 Iinfection (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) vaccines","volume":"76","author":"NJ Epsi","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pcbi.1013192.ref032","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28164","article-title":"Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster","volume":"95","author":"J Favresse","year":"2023","journal-title":"J Med Virol"},{"key":"pcbi.1013192.ref033","doi-asserted-by":"crossref","first-page":"100651","DOI":"10.1016\/j.eclinm.2020.100651","article-title":"Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation","volume":"29","author":"K Oved","year":"2020","journal-title":"EClinicalMedicine"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1013192","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1013192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:36:18Z","timestamp":1750862178000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1013192"}},"subtitle":[],"editor":[{"given":"David S.","family":"Khoury","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1013192","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.02.10.25322008","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}